SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-04T03:03:53.521137+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:81d7decdc23ad64b","evidence_event_ids":["evt_e870b59b654a"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-023699.txt","as_of":"2026-04-04T03:03:53.521137+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-023699.txt","company":"Skye Bioscience, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-023699.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_9e9834a1271344c6","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-023699.txt","content_type":"text/plain","enriched_at":"2026-04-04T03:25:26.428240+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"skye-20260331","final_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-023699.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-023699.txt","source_event_id":"evt_e870b59b654a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"127c3f487532b9ef","kind":"sec_filing","published_at":"20260403","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-04","2026-03-31"],"entities":[{"asset_class":"equity","name":"Skye Bioscience, Inc.","relevance":"high","symbol":"N/A","type":"company"}],"event_type":"other","information_gaps":["No details on the specific reasons for the stock option repricing beyond retention and motivation.","No information on the previous CFO's departure or reasons for the appointment of John P. Sharp."],"key_facts":["Stock options repriced to $0.6150 per share from original prices ranging from $1.055 to $14.56.","Total shares under repriced options: 2,420,978 shares.","John P. Sharp appointed as Chief Financial Officer effective March 31, 2026."],"numeric_claims":[{"label":"Total Repriced Options","value":"2,420,978"},{"label":"New Exercise Price","value":"$0.6150"}],"primary_claim":"Skye Bioscience, Inc. repriced stock options for current employees and appointed John P. Sharp as Chief Financial Officer.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"Skye Bioscience, Inc. filed an 8-K on April 4, 2026, disclosing a stock option repricing and the appointment of a new Chief Financial Officer.","topics":["SEC Filing","Corporate Governance","Executive Compensation"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Skye Bioscience, Inc. \u00b7 Filed 20260403","ticker":"SKYE","tickers":["SKYE"],"title":"SKYE filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-023699.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 10916 in events